Biocryst Pharmaceuticals Inc.
Durham, NC
- UEI
- MGXADJ6SCLJ5
- CAGE
- 4GBX7
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 4505 Emperor Blvd #200, Durham, NC 27703, USA
- Website
- biocryst.com
- Founded
- 1986
- Employees
- 251-1K
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $6,624 |
| FY2025 | -$28,792,410 |
| FY2024 | $2,658,744 |
| FY2023 | -$198,571 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $6,624 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Amneal Pharmaceuticals Of New York, LLC | Medford, NY | 325412 Pharmaceutical Preparation Manufacturing |
| Genentech Usa, Inc. | South San Francisco, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Kiniksa Pharmaceuticals (Uk), LTD. | England | 325412 Pharmaceutical Preparation Manufacturing |
| Prasco, LLC | Mason, OH | 325412 Pharmaceutical Preparation Manufacturing |
| United Therapeutics Corp | Silver Spring, MD | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Biocryst Pharmaceuticals Inc., a for-profit biotechnology company headquartered in Durham, North Carolina, supplies specialized pharmaceutical products to the federal government as a prime contractor exclusively — no subcontract activity — under the GSA Federal Supply Schedule for Pharmaceuticals and Drugs (FSS-61-IB) and a newly awarded Blanket Purchase Agreement with the VA's National Acquisition Center. The company competes in the open market without set-aside designations across all recent federal awards.
Biocryst's federal capability portfolio centers on two FDA-approved small-molecule drugs for rare and critical medical conditions: ORLADEYO (berotralstat) for hereditary angioedema and RAPIVAB (peramivir) for influenza treatment. Representative prime work includes a $69.4 million delivery order awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response on September 30, 2024, for Peramivir supply through September 29, 2025, and a newly awarded $93 million single-award BPA from the VA's National Acquisition Center (effective June 3, 2026, through June 2, 2027) covering both ORLADEYO and RAPIVAB for expedited procurement across federal healthcare programs. Biocryst has also received recurring delivery orders from the Veterans Integrated Service Network 20 for bulk ORLADEYO supplies, including a $379.9 million order awarded October 1, 2024, for berotralstat HCL 150mg capsules.
Customer concentration skews heavily toward two agencies. The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response and the VA National Acquisition Center together account for 86% of combined potential value ($447.2 million out of $628.9 million total). Within that aggregate, HHS ASPR anchors six awards at $343.6 million combined potential value — predominantly the large peramivir delivery order — while the VA National Acquisition Center holds three awards at $103.6 million. By award count, the rankings shift: Veterans Integrated Service Network 20 leads with twelve awards valued at $2.4 million combined (recurring small-to-moderate ORLADEYO orders), followed by ASPR (six awards) and the VA NAC (three awards). The National Institutes of Health National Institute of Allergy and Infectious Diseases contributes two research awards at $88 million combined potential value, indicating Biocryst's participation in federal biodefense or pandemic-preparedness R&D funding.
Biocryst holds two parent vehicles: the GSA Pharmaceuticals and Drugs Federal Supply Schedule (17 task orders, $174.8 million combined potential value) and the newly established VA NAC BPA ($93 million ceiling, single award). The FSS serves as the underlying contracting mechanism for nearly all delivery orders from Veterans Integrated Service Network regional facilities and ASPR. Activity accelerated significantly in 2024 (seven awards) and continues in 2025–2026 (three awards each year), though the recompete exposure over the next twenty-four months is minimal — only three awards with combined potential value of $541 thousand reaching ultimate completion in that window. The $93 million BPA awarded in June 2026 establishes a fresh procurement vehicle running through June 2027, reducing near-term recompete pressure. Service Contract Inventory data capture one SCI-reportable record in FY2022 valued at $655 thousand with 0.2 FTEs, reflecting Biocryst's positioning primarily as a goods/pharmaceutical supplier rather than a labor-intensive services contractor; SCI does not capture Biocryst's substantial product-delivery revenue streams on the FSS or BPA.
Quick answers
Is Biocryst Pharmaceuticals Inc. registered in SAM.gov?
Yes. Biocryst Pharmaceuticals Inc.'s SAM.gov registration is active through September 18, 2027.
Which contract vehicles does Biocryst Pharmaceuticals Inc. hold?
Biocryst Pharmaceuticals Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How does Biocryst Pharmaceuticals Inc. rank among federal contractors?
Biocryst Pharmaceuticals Inc. ranked #63 in NAICS 325412 and #91 in PSC 6505 in FY2025.
What is Biocryst Pharmaceuticals Inc.'s most recent federal award?
Biocryst Pharmaceuticals Inc.'s most recent federal contract award is Emergency orladeyo (36C24926F0152), from Veterans Integrated Service Network 9 (VHA), on May 21, 2026.
On GovTribe
See Biocryst Pharmaceuticals Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors